StreetAlpha.app
Home › Stocks › JBIO

Jade Biosciences, Inc. (JBIO)

Healthcare
$15.40
▲ +0.42%
LAST CLOSE · NOV 17

Jade Biosciences develops antibody medicines for autoimmune diseases, starting with a candidate for the kidney disease IgA nephropathy. It last closed at $15.40 on Nov 17, up 0.42% on the day.

AI Auto Pilots
Is JBIO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$163.1M
EPS (diluted)
−$1.83
Valuation
Market cap
$1.1B
69.2M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$80.4M
At Sep 30
Shareholder equity
$455.5M
Shares outstanding
69.2M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$23.0M−$23.0MFY2021FY2022: −$51.5M−$51.5MFY2022FY2023: −$75.5M−$75.5MFY2023FY2024: −$69.6M−$69.6MFY2024FY2025: −$127.4M−$127.4MFY2025

From JBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Last report
Nov 13
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated JBIO in the past 90 days, not enough for a consensus
Average 12-month target
$41.00
▲ 166.2% upside

Based on 1 analyst who set a price target on JBIO in the past 90 days. The average target is $41.00, with a high of $41.00 and a low of $41.00, compared with the last close of $15.40.

Low $41.00Avg $41.00High $41.00
Blue marker: last close $15.40
Highest target$41.00
Average target$41.00
Lowest target$41.00
Latest rating changes
GuggenheimMaintained
Nov 16Buy$41
WedbushTarget raised
Aug 11Buy$45 → $47
BTIGTarget raised
Aug 11Buy$74 → $77
UBSInitiated
Jun 15Buy$45
WedbushMaintained
Jun 2Buy$45
DateFirmActionRatingPrice target
Nov 16GuggenheimMaintainedBuy$41
Aug 11WedbushTarget raisedBuy$45 → $47
Aug 11BTIGTarget raisedBuy$74 → $77
Jun 15UBSInitiatedBuy$45
Jun 2WedbushMaintainedBuy$45
Loading…

Technical Analysis

JBIO · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock is 2% above its 20 day and 2% above its 50 day average. It is 18% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the 50 day average at $15.15, and the nearest resistance the swing high (Oct 22) at $15.44.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 6.7%/day
Key levels
$28.0052 week high+81.8%
$18.23100 day average+18.4%
$18.22200 day average+18.3%
$16.27Pivot R1+5.6%
$15.44Pivot+0.3%
$15.44Swing high (Oct 22)+0.3%
$15.40Last close
$15.1550 day average−1.6%
$15.0420 day average−2.3%
$14.56Pivot S1−5.5%
$14.28Swing low (Jun 9)−7.3%
$10.9852 week low−28.7%
Indicators
RSI (14)51.52Middle of its rangeNeutral
MACD0.19Above its signal lineBullish
Stochastic57.5Middle of its rangeNeutral
ADX (14)19.5No clear trend
Williams %R-48.8Oversold below −80, overbought above −20Neutral
CCI (20)45.8Oversold below −100, overbought above 100Neutral
Rate of change+5.7%Change over 10 sessionsBullish
ATR (14)$1.04Typical daily range, 6.7% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for JBIO

What happened before

See how JBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow JBIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How JBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in JBIO in the last 90 days.

Loading…

See today’s whale options flow across the market →

JBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲97 buying vs 56 selling
  • ▲Held by funds +12.9 pts
  • ▲Funds holding +7
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding162155+4.5%
In funds' top 1057−28.6%
Held by funds118.3%105.4%+12.9 pts
New / increased28 / 6951 / 60−12.6%
Reduced / sold out34 / 2226 / 16+33.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See JBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JBIO is in one of them and how their past JBIO trades turned out.

JBIO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered JBIO in an article yet. Here's the latest on the wider market.

About Jade Biosciences

Jade Biosciences is a biopharmaceutical company based in Waltham, Massachusetts, that is developing antibody medicines for people with autoimmune diseases. Its main candidate, JADE101, targets a signaling protein called APRIL and is being developed first for IgA nephropathy, a progressive kidney disease. The company is also developing JADE201, which targets the BAFF receptor on B cells, for several autoimmune disorders. Its products are still in clinical trials and are not yet sold to patients.

Headquarters
Waltham, MA